| High Profitability and Low Valuation for Gilead (EN, MotleyFool) |
| Vertex Is the Next Gilead Sciences or Alexion (EN, TheStreet.com) |
| Will Gilead Sciences Help You Retire Rich? (EN, MotleyFool) |
| Gilead Sciences 1Q profit down on Pharmasset costs (EN, Yahoo) |
| Gilead profit falls after acquisition costs (EN, Market Watch) |
| Gilead, Bristol Shine at EASL Conference (EN, MotleyFool) |
| eBay, Gilead Sciences: S&P Gainers (EN, TheStreet.com) |
| Qualcomm, Gilead Sciences: Money Flow Leaders (QCOM, GILD) (EN, The Wall Street Journal Deutschland) |
| Market Check: Gilead, Human Genome Lead Biotech Surge (EN, The Wall Street Journal Deutschland) |
| Gilead Sciences: S&P Intraday Gainer (EN, TheStreet.com) |
| Gilead, Bristol Put Profits Ahead of Best Care for Hep C Patients (EN, TheStreet.com) |
| Gilead Soars on Promising Hepatitis C Drug Results (EN, The Wall Street Journal Deutschland) |
| Gilead Soars on Promising Hepatitis C Drug Results (EN, Barrons) |
| Gilead, Bristol Hep C Drug Data Arrives at EASL (EN, TheStreet.com) |
| Bristol-Gilead Hep C Drug Data Leaks (EN, TheStreet.com) |
| GIlead And The Future of HIV Therapy (EN, TheStreet.com) |
| Decoding Biotech and Finding Opportunity in Gilead (EN, MotleyFool) |
| Decoding Biotech and Finding Opportunity in Gilead (EN, MotleyFool) |
| 2 Positive Signs for Gilead Sciences (EN, MotleyFool) |
| Hot Stock der Wall Street: Gilead Sciences (finanzen.net) 
Nach der Milliarden-Übernahme des US-Biotech-Konzern Pharmasset und des anschließenden Rückschlags eines Patienten-Test ging der Kurs von Gilead Sciences in die Knie - eine gute Kaufgelegenheit. mehr |
| Gilead, HIV Drugmakers, Rise On Pills As Prophylactics (EN, Barrons) |
| What's Going On At Gilead (EN, MotleyFool) |
| Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon (EN, TheStreet.com) |
| Gilead Sciences Shares Dropped: What You Need to Know (EN, MotleyFool) |
| Gilead sinks 15% on hepatitis C study (EN, Market Watch) |
| Gilead Suffers First Hep C Drug Setback (EN, TheStreet.com) |
| Gilead: A Solid Investment (EN, MotleyFool) |
| After Hours: Gilead, Edwards may be active after hours (EN, MarketWatch) |
| Options Players Jump Into Gilead After Hep C Data, Ford And GM Burn Rubber On Jobs Report (EN, Forbes) |
| Gilead Sciences Soars On "Striking" Clinical Trial Data (EN, Benzinga earnings) |
| Gilead Sciences Shares Surged: What You Need to Know (EN, MotleyFool) |
| Gilead Sciences Meets on the Top Line, Misses Where it Counts (EN, MotleyFool) |
| Idenix Falls Casualty to Gilead Hep C Hoopla (EN, TheStreet.com) |
| Gilead shares gain on higher fourth-quarter profit (EN, Market Watch) |
| Gilead Woes With New Hep C Data, Boxing Out Poor 2012 Guidance (EN, TheStreet.com) |
| Gilead Sciences 4Q profit rises on HIV drug sales (EN, Yahoo) |
| Gilead Sciences steigert Umsatz und Gewinn, (Aktiencheck) 
Das amerikanische Pharma- und Biotechnologieunternehmen Gilead Sciences hat die Zahlen für das Schlussquartal vorgelegt. mehr |
| Forbes Earnings Preview: Gilead Sciences (EN, Forbes) |
| Has Gilead Sciences Become the Perfect Stock? (EN, MotleyFool) |
| Is Gilead Sciences' Stock a Bargain by the Numbers? (EN, MotleyFool) |